Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety
Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.
You may also be interested in...
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
While more money will be poured into COVID-19 vaccines, the pandemic's effects will be felt on overall growth of global medicine use following disruptions to patient engagement with healthcare, a new report from the IQVIA Institute for Human Data Science predicts.
The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.